SPY310.52+2.16 0.70%
DIA257.31-0.56 -0.22%
IXIC10,154.63+95.86 0.95%

Merck Reports FDA Approves KEYTRUDA For Treatment Of Patients With Recurrent, Metastatic Cutaneous Squamous Cell Carcinoma Not Curable By Surgery Or Radiation

Benzinga · -